and extent of platelet aggregation with the change in optical transmittance but differs in use of fibrinogencoated microbeads. This microbead technology allows the use of whole blood, eliminating the need for sample preparation. 7 The purpose of this study was to compare the Ultegra RPFA to standard platelet aggregometry and to a radiometric receptor binding assay (RBA). A secondary objective was to determine whether the Ultegra RPFA provides rigorous precision independent of the experience or expertise of the operator.
Methods

Patient enrollment
The protocol was approved by the Institutional Review Boards of the participating medical centers. After informed consent was obtained, patients 21 years of age or older who underwent PCI with abciximab treatment (0.25 mg/kg bolus, then 0.125 µg/kg/min for 12 hours) were enrolled at 4 centers: The Cleveland Clinic (Cleveland, Ohio), The Lindner and Ohio Heart Health Centers at The Christ Hospital (Cincinnati, Ohio), University of Massachusetts Medical Center (Worcester, Mass), and Wake Forest University School of Medicine (Winston-Salem, NC). Patients were excluded if the platelet counts within 48 hours of study entry were outside the range of 125 to 350 × 10 9 /L or if they had undergone treatment with thrombolytic agents within 24 hours of study entry.
Patient characteristics
Demographic information and medications received within 7 days of study entry were recorded. The patient's clinical presentation was categorized as stable angina, unstable angina, or acute myocardial infarction. Interventional procedures and outcomes were recorded.
Blood samples
Complete blood count, platelet count, and activated clotting time assays were performed at all 3 time points. For the platelet function studies, 30 to 35 mL of blood were collected in 3.2% sodium citrate tubes. Blood was drawn at the following 3 time points: 1, baseline, before abciximab administration; 2, during, within 1 hour after abciximab bolus administration; 3, post, 24 hours after abciximab bolus administration or at time of discharge, whichever occurred first. In general, blood collection was from a femoral artery sheath for the baseline and 1-hour samples and from a venous source for the 24-hour sample with a 21-gauge needle. Samples were collected from indwelling catheters after a ≥10 mL discard to clear the line. In samples obtained via direct venipuncture, a 21-gauge or larger needle was used and the first 5 mL were discarded. The protocol mandated that assay procedures were to be completed within 1 hour (Ultegra RPFA), 2 hours (RBA), and 2.5 hours (platelet aggregometry).
Platelet and plasma preparation
Samples for aggregometry and RBA were transferred to 5-mL polypropylene tubes and then spun at 150g for 15 minutes. Platelet-rich plasma (PRP) then was transferred to new 5-mL polypropylene tubes. The platelet count was determined on both whole blood and PRP samples with a whole blood cell counter. Platelet-poor plasma was prepared with spinning the blood remaining in the tubes after PRP removal at 800g for 10 minutes.
Platelet aggregometry
Platelet aggregometry was performed with PRP and plateletpoor plasma with optical detection with a ChronoLog (Havertown, Pa) aggregometer and their standardized Aggro-Link software. The agonist was adenosine diphosphate (20 µmol/L).
Abciximab binding assays
The radiometric abciximab binding assay used in this study was performed as previously described. 8 
Ultegra rapid platelet-function assay
The Ultegra RPFA is an automated turbidometric whole blood assay designed to assess platelet function on the basis of the ability of activated platelets to bind fibrinogen. 7 Fibrinogen-coated beads agglutinate in proportion to the number of unblocked platelet glycoprotein IIb/IIIa receptors. Thrombin receptor activating peptide (iso-SFLLRN), is incorporated into the assay to induce platelet activation without producing fibrin formation. As activated platelets bind to and agglutinate the fibrinogen-coated beads, an increase in light transmittance is detected. The rate and extent of aggregation are measured as the change of absorbance over a fixed time interval and are reported as platelet aggregation units (PAUs).
Interuser variability of ultegra RPFA
Typical "point-of care" users (nurses, research coordinators, catheterization laboratory personnel, and physicians) were compared with laboratory scientist users. Both groups of personnel were similarly trained on the RPFA. Only the baseline time point was compared. A total of 173 patients were considered evaluable for this portion of the study. Nineteen patients were excluded from the analysis because 1 of the Ultegra RPFA results from either the intended user or the laboratory scientist was not obtained or, in 1 case, because the values could not be compared because of marked hemolysis.
Precision of the three assays
A single center sub-study was performed at the Wake Forest University School of Medicine site to compare the precision of the 3 platelet function assays by running duplicates of all assays at all time points in 22 patients.
User replicate assay agreement
At 3 centers (The Cleveland Clinic Foundation, The Lindner Center, Wake Forest University School of Medicine), an additional sub-study was performed to determine the degree of variability when the point-of-care user performed Ultegra RPFA duplicate assays on samples obtained at each of the 3 time points. A total of 65 additional patients were enrolled. Exclusion and inclusion criteria were identical, and patient characteristics were similar. All patients underwent PCI with abciximab treatment. Furthermore, an additional 16 patients were enrolled at 2 centers (The Lindner Center and Wake Forest University School of Medicine) to determine the precision of the Ultegra RPFA device in performing 6 assays on the same patient at each of the 3 time points.
Results
Patient disposition
A total of 192 patients were enrolled in the study at 4 centers. Table I summarizes the disposition of patients. The first 45 patients entered during this time were excluded from the comparison of the 3 methods because of problems with PRP preparation. However, because PRP preparation is not necessary for the Ultegra RPFA device, these 45 patients were evaluated for Ultegra RPFA stand-alone measurements. These measurements include the establishment of the PAU value range and the baseline comparison of values obtained by the intended (point-of-care) user to those obtained by the laboratory scientist. The protocol was amended, and enrollment was resumed after standardization for the preparation of PRP and the institution of new guidelines to perform PRP platelet counts. After these changes were made, 147 additional patients were enrolled, 120 (82%) of whom were evaluable for the comparison of the 3 assays.
A total of 72 patients were excluded. Of these, 45 patients were excluded because of protocol change, as previously discussed. Twenty-seven additional patients were excluded because of missing data points, a significant drop in the PRP count from baseline, the discovery of exclusion criteria after entry, instrument malfunction, or other reasons, such as the collection of the baseline sample after abciximab administration. There were 120 patients with complete data for all assays at all time points, hereafter referred to as "evaluable" patients. Table II shows the demographic characteristics, cardiac risk factors, and the diagnoses of 189 patients.
Patient characteristics
(Three patients in the nonevaluable group had incomplete demographic information).
Concomitant medications
More than 90% of subjects had received aspirin, and 12.7% had undergone treatment with either clopidogrel or ticlopidine before enrollment. Nonsteroidal antiinflammatory drugs were administered to 3.7% of the patients. The average infusion time for abciximab was 11.8 ± 1.6 hours. The interval between the bolus of abciximab and the collection of the "during" sample was 24 ± 22 minutes, and the interval from stopping abciximab infusion to the collection of the "post" sample was 10.5 ± 2.6 hours.
Procedural outcomes
PCI was successful in 98% of the cases. Significant bleeding occurred in 7% of cases, and death in 1%.
Regression analyses
Linear regression results for the 120 evaluable patients are presented in Table III , and the actual regression lines comparing the methods are shown in Figures 1, 2 , and 3. A potential limitation of this analytic approach is that 3 samples from the same individual were analyzed, rather than independent samples from different patients at each time point. The Pearson corre- 
Orthogonal (Deming) regression analysis
The data were reanalyzed with orthogonal regression. The correlation coefficient for the Ultegra RPFA versus RBA was 0.89, for Ultegra RPFA versus aggregometry was 0.89, and for aggregometry versus RBA was 0.87. As with the linear analysis, the orthogonal regression showed substantial agreement (equivalence) between the different methods.
Interpretation of the linearity between the three assays
The Pearson correlation coefficients suggest a strong degree of interchangeability and equivalence for quantitative use. Although the relationship is quite linear throughout the range of Ultegra RPFA when compared with RBA, the relationship with aggregometry is less linear, but so too is the relation between RBA and aggregometry. It is likely that the lack of better linearity with aggregation assays is related to a threshold effect with this assay, arising from the requirement for occupancy of a certain proportion of fibrinogen receptors before inhibition of aggregation is observed. For example, Mascelli et al 9 have found a lower extent of inhibition (49% ± 14.2%) with turbidometric aggregometry at 12 hours after cessation of abciximab therapy relative to RBA (69% ± 12.7%).
Time course data expressed as a percent of baseline Figure 4 shows the degree of inhibition measured at during and post time points for each assay. The Ultegra RPFA data indicate that more than 90% of the patients achieved >80% inhibition at the during time point, which is consistent with several prior studies of abciximab. 2,9-11 As shown in Figure 4 , all 3 assays recorded marked inhibition of platelet aggregation during the 1st hour after the abciximab bolus administration and a partial recovery of platelet function at the post time point.
Overall, the Ultegra RPFA had a slightly lower standard deviation than the RBA. The Ultegra RPFA recorded a lower value (greater extent of inhibition) at both the during and the post time points relative to RBA and platelet aggregometry. The lower value at the during time point can be partially explained by the non-zero bias of the other methods. Platelet aggregometry, as previously reported, showed the most variability of the 3 methods. 9 
Point of care user versus laboratory scientist analysis
A total of 173 patients were enrolled in this portion of the study. Nineteen patients were excluded because 1 of the time points from either the intended user or the laboratory scientist was not obtained or, in 1 case, because of marked sample hemolysis. An orthogonal regression analysis comparing the values obtained by point of care users with those obtained by the laboratory scientist was performed, and the resulting correlation coefficient was 0.80.
Figure 2
Linear regression between Ultegra rapid platelet-function assay (RPFA) and aggregometry (all sites, 120 patients). Results from platelet aggregometry and from Ultegra RPFA at all 3 time points were plotted. Regression line shows linear relationship (r = 0.89) between maximum aggregometry slope and platelet aggregation unit (PAU). Figure 5 shows the estimated 95% central ranges of PAU values for the baseline and during measurements. There is no overlap between the baseline and during ranges, providing the clinician with an unambiguous interpretation. Figure 6 shows that there is no significant relationship (r 2 = 0.10) between time elapsed from cessation of abciximab infusion and PAU value. Because of this variation in time from abciximab cessation (2 to 23 hours) to post blood draw, a PAU value range for the post time point could not be established. Figures 7, 8, and 9 show PAU values in relation to platelet count, hematocrit, and fibrinogen. No significant trend in hematologic parameters relative to PAU values was evident in any of these plots. The mean platelet count for the evaluable patients at baseline was 201,000/µL whole blood. At the during time point, the mean platelet count fell to 176,000/µL (88% of baseline), and the post platelet count was 106% (208,000/µL) of baseline. Hematocrit at the during time point dropped to a mean 96% of baseline value and recovered to 99% at the post time point. One recent study reported an association between high platelet count in PRP and a diminished inhibition in response to abciximab. 12 However, the GOLD study 3 of 500 patients showed that whole blood platelet counts in the range of 71,000/µL to 633,000/µL did not affect the inhibition by abciximab as detected with the Ultegra RPFA at any of the time points studied here.
Platelet aggregation units value range analysis
Potential confounding factors
Another potential confounder is the presence of other medications that may influence platelet inhibition. Table IV 
Figure 5
Ultegra rapid platelet-function assay value range. Figure shows 95% central platelet aggregation unit (PAU) value ranges for Ultegra rapid platelet-function assay baseline and "during" PAU values. PAU value range for baseline is 125 to 330 PAU. A platelet function inhibition ≥80% corresponds to "during" value of 0 to 44 PAU.
difference when these medications were present, although an evaluation of the effects of individual medications on PAU values will require further investigation.
Precision of the three assays
Twenty-two patients were enrolled for this substudy, 2 of whom were excluded: one because of an Ultegra RPFA test malfunction (bubbles in the cartridge) and 1 because the patient was inadvertently discharged before collection of the post blood sample.
A potential limitation in this method of comparison is that the PRP necessary for both the RBA and aggregom-
Figure 6
Effect of variation in recovery time: from termination of abciximab infusion to Ultegra rapid platelet-function assay (RPFA) "post" sample. Display of relationship of Ultegra rapid platelet-function assay (RPFA) and baseline fibrinogen. Scatter plot shows fibrinogen and baseline Ultegra RPFA platelet aggregation unit (PAU) values (n = 483 assays). No apparent relationship is seen between baseline fibrinogen levels and PAU values.
etry was not prepared separately for each of the duplicate assays (because of sample volume requirements), thereby eliminating any variability that may occur in the centrifugation and transfer of the PRP. This could result in the overestimation of the precision of RBA and aggregometry. Nevertheless, the Ultegra RPFA showed greater precision relative to aggregometry at all 3 time points. The RBA showed the best overall precision. Figure 10 is a box plot of these data.
User replicate assay agreement
An orthogonal regression analysis showed excellent agreement (r = 0.99) between duplicate measurements on the 65 patients. At 2 centers (The Lindner Center and Wake Forest University School of Medicine), an additional 16 patients were enrolled to determine the precision of the Ultegra RPFA device in performing 6 replicate assays on the same patient at each of the 3 time points. The baseline coefficient of variation was 6.7%, with a maximum of 10.5%. Because the mean values at the during and post time points are so low, the values were calculated as a percentage of baseline. The average percent difference for the during samples was 5%, with a maximum difference of 8%, and for the post samples, the average percent difference was 11%, with a maximum of 19%.
Discussion
A point-of-care assay of platelet function should not require expensive equipment and should be rapid and simple to perform without advanced technical expertise. The purpose of this study was to compare the Ultegra RPFA with standard assays used to measure platelet inhibition in response to abciximab. In 120 patients who underwent PCI with abciximab treatment, the degree of platelet inhibition at 3 time points as determined with the Ultegra RPFA correlated well (r = 0.89) with platelet aggregometry, the established gold standard for measuring platelet function. When compared with a second well-characterized method (RBA), there was also a close correlation (r = 0.89). Good agreement (r = 0.80) also was obtained between point-of-care user and laboratory scientist measurements, suggesting that results with Ultegra RPFA are independent of the operator. In a sub-study of 22 patients, the precision of duplicate measurements with the Ultegra RPFA was determined to be slightly better than aggregometry and slightly inferior to RBA. Finally, the baseline values obtained with the Ultegra RPFA did not differ significantly as a function of concomitant medications, hematologic variables, or demographics.
The time necessary to prepare PRP through centrifu-
Figure 10
Box plots show 10th, 25th, 50th, 75th, and 90th percentiles and outliners for percentage difference in replicate measurements. Box plot shows precision of each of 3 methods when duplicate assays are completed at each time point (n = 20 patients). Receptor binding assay (RBA) showed best precision, followed by Ultegra rapid plateletfunction assay (RPFA). Aggregometry had poorest precision. Horizontal line within box is 50% percentile (median) difference in replicate measurements, whereas top and bottom borders of each box represent 90th and 10th percentiles, respectively. Measurements outside box (outliers) are plotted as individual points.
gation and to perform the platelet aggregation assays makes turbidometric aggregometry impractical in a busy interventional or outpatient practice. 6 Likewise, extensive sample preparation, equipment expense, need for isotopes, and the required training make the RBA method undesirable in an interventional setting. A method that may have potential for use within a catheterization laboratory is modified platelet aggregometry with an impedence technique. 9 The platelet function analyzer PFA-100 (Dade Behring, Miami, Fla) and a device that measures shear-induced platelet deposition (the Cone and Platelet Analyzer [a noncommercially available device fabricated by these investigators]) also show promise for monitoring glycoprotein IIb/IIIa therapy. 14 If the degree of platelet inhibition during PCI does not correlate with clinical efficacy, or safety, there would be little use for a device that can monitor individual patient responses to glycoprotein IIb/IIIa inhibitors. Recent studies, however, have shown a significant interindividual variation in antiplatelet effect from abciximab. 9, 10, 15 Furthermore, evidence of an association between degree of platelet inhibition and the occurrence of major adverse cardiac events is accumulating. 3, 15 The GOLD study suggested that the level of platelet function as measured with the Ultegra RPFA device is an independent predictor of MACE after PCI. In that study, one quarter of the patients who underwent intravenous glycoprotein IIb/IIIa inhibitor therapy did not achieve ≥95% inhibition at 10 minutes after glycoprotein IIb/IIIa inhibitor bolus administration, and this group had a significantly higher incidence rate of major adverse cardiac events (MACE) (14.4% versus 6.4%; P = .006). In this study, the correlation between percent platelet inhibition and MACE was similar in patients with abciximab treatment and in the 16% of patients treated with small molecule inhibitors, suggesting that the RPFA will be useful for monitoring therapy with all glycoprotein IIb/IIIa inhibitors.
The use of glycoprotein IIb/IIIa is expanding to include medical therapy for acute coronary ischemic syndromes, including combined therapy with thrombolytic agents for acute ST elevation myocardial infarction. However, for all of these uses, it remains to be shown that monitoring of platelet function and adjusting therapy to account for interindividual variations in antiplatelet response will improve efficacy or safety.
The advent of agents that therapeutically inhibit platelet response in thrombogenic environments introduces a need for accurately measuring the magnitude of that inhibition. On the basis of the results of this study, the Ultegra RPFA appears to offer a simple and standardized method of measuring platelet function in response to abciximab, a frequently used glycoprotein IIb/IIIa inhibitor. As such, this device represents an important advance, enabling clinicians and researchers to correlate the degree of platelet inhibition with clinical outcome.
